Patented molecules clock a high growth rate in Indian cardiovascular market

In January 2020, the Delhi High Court granted an injunction restraining domestic companies such as Cipla, Torrent, Emcure, and Alkem from launching their brands

Globally, the cardiovascular medicines market is highly generic, but in India, a handful of patented brands are among the fastest-growing molecules. The cardiovascular segment has been clocking a 15 per cent compound annual growth rate in the past ten years. Three patented molecules have been growing at a fast clip in the Indian market — Apixaban, the Sacubitril and Valsartan combination, and Rivaroxaban.

Novartis’ Vymada went from Rs 90 lakh in sales in March 2017, to Rs 123 crore in March 2020. Local players such as Lupin, Cipla, and Natco have launched the licensed versions of the drug. The earliest expiry